VACCINE

Human Vaccines And Immunotherapeutics • 2014
Annual World Vaccine Congress 2014:
a re-evaluation of the value proposition
for increasing vaccine thermostability
Author information
Derwand R.
Leukocare AG; Martinsried
Munich, Germany
Abstract
The 14th Annual World Vaccine Congress was held in Washington
DC, March 24-26, 2014 (http://www.terrapinn.com/vaccine2014).
More than 400 experts from different regions participated in this
scientific event for vaccine professionals from industry, academia,
non-profit organizations and government to discuss challenges and
successes from all the major vaccine stakeholders. In more than 70
presentations, round tables, and plenary discussions major topics like
emerging and re-emerging infectious disease, vaccine production,
and innovative technologies were debated. While most contributions
focused on specific questions in vaccine research development, some
like the one by a representative of the Bill and Melinda Gates Foundation
(BMGF) reported about supply chain, logistics topics, and
challenges in vaccine implementation.
http://www.ncbi.nlm.nih.gov/pubmed/?term=25483655
“While most contributions
focused on specific questions in vaccine
research development, some like the one by a
representative of the Bill and Melinda Gates
Foundation (BMGF) reported about
supply chain, logistics topics, and
challenges in vaccine implementation.”